TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05832073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural full human monoclonal antibody CBB 1 injection
Description: Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Human Immunoglobulin (HRIG)
Description: Active ingredient: Rabid human immunoglobulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natural full human monoclonal antibody CBB 1 injection placebo
Description: Composition: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
Study: NCT06025071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: Dosage form: Tablets; Dosage: 0.5mg; Frequency: Once daily; Duration: From randomization to one-year follow-up is completed.
Study: NCT05411757

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IBR900 combined with Lenvatinib
Description: IBR900 cell injection: 4.0×10\^9 cells, D1,D3 of each cycle. Lenvatinib: body weight ≥ 60kg, 12mg/qd; body weight \< 60kg, 8mg/qd; administered continuously from D5 of the first cycle

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IBR900 combined with Bevacizumab
Description: IBR900 cell injection: 4.0×10\^9 cells, D1,D3 of each cycle. Bevacizumab:15mg/kg, D1 of each cycle.
Study: NCT05431894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laguna Coach Intervention Group
Description: Behavioral and mental support was delivered through personal interactions with Laguna Coaches via phone, video, or web chat. Behavioral and mental support was individualized to best match each patient's needs and strengths. Support was provided to participants through human interactions over approximately 30 days.
Study: NCT05577533

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: O-Kidia game battery
Description: Children will be playing on a series of games with a touch screen tablet while video and digit trajectories data will be collected from this mobile device to analyze eye-, face-, sound-recognition.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: O-Brain
Description: Electrical recordings and measurements - A mobile EEG headset will be used during the visit - 30 min
Study: NCT05076357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: -30% of participants total energy requirements
Study: NCT05832073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized rabies vaccine for human use (Vero cells)
Description: Active ingredient: inactivated rabies virus fixed poison

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lyophilized rabies vaccine for human use (Vero cells)
Description: Active ingredient: inactivated rabies virus fixed poison

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized rabies vaccine for human use (Vero cells)
Description: Active ingredient: inactivated rabies virus fixed poison
Study: NCT04833465

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT05979519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh Funds for Mom's
Description: Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.~Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical care
Description: Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks or be provided the medically tailored meals for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medically Tailored Frozen Meals
Description: Participants will enroll in the MTM program. Once enrolled participants will receive 10 frozen meals delivered by Door Dash to their home each week for 12 weeks.
Study: NCT05076266

Intervention type: OTHER
Intervention: Questionnaire
Description: Complete the survey questions
Study: NCT05541185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil
Description: 1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Naproxen and lidocaine gel
Description: 1 ml of Naproxen and lidocaine gel was applied to both knee areas of the Naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Massage
Description: 1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
Study: NCT05150652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1mg
Description: Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg
Description: Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.
Study: NCT05285592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Transplantation
Description: Fecal Transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study: NCT05656937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal jugular venous cannulation
Description: internal jugular venous cannulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: internal jugular venous cannulation
Description: internal jugular venous cannulation
Study: NCT05270096

Intervention type: OTHER
Intervention: Advice
Description: non-interventional study
Study: NCT06506578

Intervention type: RADIATION
Intervention: Radiation
Description: Radiation
Study: NCT05076357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: -30% of participants total energy requirements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold intervention
Description: Sessions of 90min each every 2nd day involving cold exposure
Study: NCT04449445

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Isocaloric and iso-nitrogenous standard enteral tube feeds
Description: Dietary supplement
Study: NCT05274178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P hearing aid labeled as Prescriptive
Description: The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as prescriptive in view of the participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P hearing aid labeled as Prescriptive
Description: The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as prescriptive in view of the participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P hearing aid labeled as OTC
Description: The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as OTC in view of the participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P hearing aid labeled as OTC
Description: The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as OTC in view of the participant.
Study: NCT05191004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-422
Description: NUV-422 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-422
Description: NUV-422 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-422
Description: NUV-422 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant
Study: NCT00475527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole,clarithromycin,amoxicillin (or metronidazole)
Study: NCT05334628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Erector spinae plane block
Description: Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postperative Erector spinae plane block
Description: Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the lateral decubitus position.
Study: NCT05217394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTHIG
Description: Occupational Therapy Handwriting Intervention Guideline
Study: NCT05194930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The ABC of Insomnia (Acceptance and the Behavioral Changes to treat Insomnia)
Description: 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) provided by a trained instructor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Insomnia
Description: 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
Study: NCT06584318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia intervention
Description: The intermittent hypoxia protocol refers to 6 cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
Study: NCT05073926

Intervention type: OTHER
Intervention: No intervention is part of the study protocol
Description: No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.

Intervention type: OTHER
Intervention: No intervention is part of the study protocol
Description: No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
Study: NCT06423924

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05225363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-cells
Description: Receive TAG72-CAR T cells IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT05199480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobacco flavored liquid type 1
Description: A commercially available cartridge-based device with tobacco flavored liquid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco flavored liquid type 2
Description: A commercially available cartridge-based device with tobacco flavored liquid.
Study: NCT04809909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral stimulation of acupuncture points (PSAP)
Description: Electrode leads will be implanted at Bladder 25-bilateral (BL25), the acupoint commonly used for relief of chronic Low Back Pain in standardized acupuncture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve field stimulation (PNFS)
Description: Electrode leads will be implanted at the region of pain.
Study: NCT05605665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once twice a week, for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once twice a week, for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: Rapamycin 0.5ml was taken orally once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rapamycin
Description: Rapamycin 0.5ml was taken orally once per day
Study: NCT06172374

Intervention type: GENETIC
Intervention: Sano Genetics Testing Kit
Description: Genetic testing spit collection tubes for DNA testing

Intervention type: GENETIC
Intervention: Sano Genetics Testing Kit
Description: Genetic testing spit collection tubes for DNA testing

Intervention type: GENETIC
Intervention: Sano Genetics Testing Kit
Description: Genetic testing spit collection tubes for DNA testing
Study: NCT05731830

Intervention type: OTHER
Intervention: Data extraction
Description: The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. We will investigate: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, and the ArpaLazio website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php), which provides the concentration of NO, NO2, NOx, PM10, PM2.5, O3, CO, C6H6, SO2 expressed in micrograms per cubic meter (µg/m3). Hourly data are available for all gaseous pollutants, while the levels of PM10 and PM2.5 are expressed daily. Data will be obtained from the air quality monitor closest to each participant's residence that was active for the entire year, and short-term (daily and weekly) and long-term (annual) air pollution exposure will be quantified as daily, weekly, and annual average 24-h pollutants level of measurements before TTS.

Intervention type: OTHER
Intervention: Clinical follow-up
Description: All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACE, defined as the composite of all-cause mortality, non-fatal MI, transient ischemic attack (TIA)/stroke, and hospitalization for heart failure, and the recurrence of TTA in the past months will be investigated and collected.
Study: NCT04449445

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestle IMPACT AR
Description: Dietary supplement
Study: NCT05191004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant
Study: NCT06475326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab ,20mg/Kg per time, Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 100 MG
Description: Oxaliplatin: 60mg/m2, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome
Description: Irinotecan Liposome: 50mg/m2, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate
Description: Calcium Folinate: 400mg/m2, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil: 2400mg/m2, Q2W
Study: NCT06424548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Sarpogrelate
Description: Aspirin 100mg plus Sarpogrelate 100mg

Intervention type: DRUG
Group type: OTHER
Intervention: Traditional administration of Clopidogrel
Description: Aspirin 100mg plus Clopidogrel 75mg
Study: NCT04902001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary weight loss
Description: The adolescents will follow a 12-week intervention combining nutritional education, physical activity 3 times per week and psychological supports.
Study: NCT05332301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat test meal
Description: Ingestion of a mixed macronutrient breakfast meal providing 846 kcal, of which 58% is fat, 29% is carbohydrate and 13% is protein.
Study: NCT05800470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fNIRS-based neurofeedback with motor imagery
Description: A multichannel wearable fNIRS (NIRSport2, NIRx Medical Technologies LLC, Glen Head, NY, USA) will be used to detect the cortical activity in SMA. The HbO concentration will be processed and displayed as a visual feedback during MI training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesthetic motor imagery
Description: Participants will be asked to practice MI with kinesthetic strategy in the first-person perspective for balance and gait tasks in 10 mins. After the MI training, they will receive 20-min balance and gait training, the same as in experimental group.
Study: NCT05782504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered teleprehabilitation
Description: Education about the consequences of stress and low physical activity levels with examples of how improving stress tolerance and physical activity can influence QoL and oncological treatment outcomes.~Exercise therapy based on shared-decision making and using a patient-centered approach. The goal will be to strive for 150-220 min. of moderate physical activity/week, including a home exercise program (at least 1 session/week) of 30-45 min. moderate aerobic exercise, 20 min. of strength training and 10 min. cool down. The latter is guided by Physitrack software.~Stress management, including questioning personal stress experiences and perceptions, relevant stressors, and stress coping strategies. Next, 3 different relaxation strategies will be explained. Also, cognitive-emotional approaches to stress management and identification of uplifts will be introduced.~Motivational interviewing will be used during the whole intervention.
Study: NCT06037109

Intervention type: DEVICE
Intervention: Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test
Description: Previously collected urine samples will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test

Intervention type: DEVICE
Intervention: Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test
Description: Previously collected urine samples will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
Study: NCT04964206

Intervention type: PROCEDURE
Intervention: Neuraxial labor analgesia
Description: Epidural or combined spinal-epidural labor analgesia will be performed according to the routine practice of each study center.

Intervention type: PROCEDURE
Intervention: No neuraxial labor analgesia
Description: Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
Study: NCT05723094

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ga-Al-As diode laser (Ilase, USA)
Description: The laser parameter used in previous study： Laser type：Ga-Al-As Wavelength：940 nm Emission type：Continuous Irradiation dosage/per tooth：75J/cm2 Application technique：Direct contact with the mucosa Exposure time per point：6 second Laser classification：3B Laser application time：Once in a month (4-week intervals) for the maxilla and mandibular incisors and canines Output：100Mw Diameter of the optical fiber：0.04 cm2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Before the orthodontic retention phase, those who did not apply the Ga-Al-As diode laser (Ilase, USA) were the control group.
Study: NCT06404957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Applied
Description: Mindfulness-Based Practices is planned to be an 8-week program of mindfulness meditation and gentle Hatha yoga taught in an online class for up to 14 participants.
Study: NCT05025891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Patients are randomized into groups in which there are either teleconsultations alone or with the help of a mediator to carry out their follow-up care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Patients are randomized into groups in which there are either teleconsultations alone or with the help of a mediator to carry out their follow-up care
Study: NCT06404957

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Control groups
Description: No intervention will be made in this group.
Study: NCT05576233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: disinfection of the surface that the blood culture is taken
Description: lood cultures can be routinely performed with alcohol/povidine-iodine or alcohol/chlorhexidine. The topical disinfectants used in the two applications are the topical disinfectants included in the guidelines and currently applied in our hospital.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: disinfection of the surface that the blood culture is taken
Description: lood cultures can be routinely performed with alcohol/povidine-iodine or alcohol/chlorhexidine. The topical disinfectants used in the two applications are the topical disinfectants included in the guidelines and currently applied in our hospital.
Study: NCT05848102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: FORXIGA（Dapagliflozin Tablets), manufacturer/marketer: AstraZeneca, salt composition: Dapagliflozin (10mg), one tablet once and once a day.
Study: NCT06169878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable lower limb abduction apparatus
Description: To ensure abduction in the lower extremities after total hip replacement surgery, a specially adjustable apparatus developed according to the height and weight of each individual was used.~This developed product was used by patients while they were lying down and walking.
Study: NCT05321576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (ESPB) technique without opioid use
Description: Local anesthetic injection to the erector spinae muscle plane at T5 level on the operation side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (ESPB) technique without opioid use
Description: Local anesthetic injection to the erector spinae muscle plane at T5 level on the operation side.